Zhejiang Huahai Pharmaceutical Co., Ltd. Class ASSE: 600521

"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing

Sep 19, 2026 · Issued by Zhejiang Huahai Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Convening the 2026 Semi-annual Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Zhejiang Huahai Pharmaceutical Co., Ltd. Class A

"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Overseas Marketing Authorization for the Formulation ProductsSep 15
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Pledge of Certain Shares Held by the ShareholderSep 11
Hansoh Pharmaceutical: BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETCAN (HS-20093) FOR INJECTION FOR SMALL CELL LUNG CANCER ACCEPTED BY THE NMPASep 7
"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Semi-annual Report for 2026Aug 27

All Zhejiang Huahai Pharmaceutical Co., Ltd. Class A news releases